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Neuron glia antigen-2 ((NG2), also known as chondroitin sulphate proteoglycan 4, or melanoma-associated
chondroitin sulfate proteoglycan) is a type-1 membrane protein expressed by many central nervous system (CNS)
cells during development and differentiation and plays a critical role in proliferation and angiogenesis. ‘NG2’ often
references either the protein itself or the highly proliferative and undifferentiated glial cells expressing high levels
of NG2 protein. NG2 glia represent the fourth major type of neuroglia in the mammalian nervous system and are
classified as oligodendrocyte progenitor cells by virtue of their committed oligodendrocyte generation in
developing and adult brain. Here, we discuss NG2 glial cells as well as NG2 protein and its expression and role
with regards to CNS neoplasms as well as its potential as a therapeutic target for treating childhood CNS cancers.
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Neuron glia antigen-2 (NG2) glia are chondroitin sulfate proteoglycan
4 protein, expressing cells abundantly present in the developing brain as
well as in the adult central nervous system (CNS). NG2 glia actively
proliferate and differentiate into mature oligodendrocytes, thus have
been characterized as oligodendrocyte progenitor cells (OPCs). NG2
expressingOPCs have diverse functions that include physiologic support
of neurons and synaptic signaling with NG2 protein being an important
player to execute these functions in healthy brain as well as in brain injury
repair and regeneration. Additionally, NG2 protein has also been found
to play a critical role in tumorigenesis and tumor progression. SinceNG2
expressing OPCs have been identified as the cell of origin in gliomas, it is
important to explore the role ofNG2 in gliomagenesis. Here, wewill first
review the characteristics of NG2 protein and NG2 expressing OPCs
and then discuss the role of NG2 protein in relation to gliomas and the
possibility of using NG2 as a therapeutic target.
NG2 Protein
NG2 protein, encoded by the chondroitin sulfate proteoglycan 4 gene, is
highly expressed in developing and adult CNS [1]. In extra neural tissues,NG2 was originally thought to be expressed during development in
progenitor cells like mesenchymal stem cells, chondroblasts, osteoblasts,
immature keratinocytes, muscle progenitors, and melanocytes [2].
Subsequent studies supported the presence of NG2 in various post natal
tissues that include bone marrow smooth muscle, interfollicular
epidermis in skin, musculoskeletal junctions, pancreas, lungs, eyes,
heart, and kidneys [3–6]. However, the widespread NG2 expression in
extra neural tissues during development in the undifferentiated cell state
is highly down-regulated during differentiation [7]. Pericytes that
ensheath endothelial layer of blood vessels also express NG2 [8]. In
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endothelial layer and interaction with endothelial cells [8,9]. NG2
deficiency during early development results in loss of pericyte-endothelial
association and defective formation of basement membranes in blood
vessels [10]. Below, we will further discuss the role of NG2 expression in
microvasculature associated-pericytes in relation to CNS tumors [11]. In
addition, NG2 expression in postnatal state is associated with response to
injury-induced inflammation and certain pathological conditions
including CNS tumors, soft tissue sarcomas, and melanomas [12–14].
The expression of NG2 is tightly regulated by a 1,585 base pair
promoter region upstream of translation initiation site [13]. NG2
promoter contains binding sites for p300 and CREB binding protein
which function as co-activators to regulate gene expression [13]. At
the transcription level, we have shown that NG2 mRNA is targeted
and regulated by microRNA (miR129-2), which binds 3′UTR of
NG2 mRNA [15]. Targeting miR129-2 provides potential targeting
avenues for regulating NG2 in glioma which is further elaborated in
this review.
NG2 protein is a membrane spanning proteoglycan with a molecular
weight of 252 kDa in its native form and 300 kDa in glycosylated state.
NG2 consists of a large extracellular domain with 2,225 amino acids that
makes up for 95% of the protein, a transmembrane domain with 25
amino acids, and a short cytoplasmic tail of 76 amino acids [2,16]
(Figure 1). These domains facilitate the interaction of NG2 with
extracellular and intracellular ligands to activate signaling events that are
mediated through focal adhesion kinase and MAP kinase pathways and
regulate important cellular functions such as cell proliferation,migration,
invasion, cytoskeletal reorganization, survival, chemoresistance, and
modulation of neuronal network [2,17]. In NG2 dependent signalFigure 1. The structure of NG2 protein. NG2 protein is a transmem-
brane protein that consists of a (1) large transmembrane domain
consisting of 2,225 amino acids, (2) a small transmembrane domain
(25 amino acids) and (3) a short cytoplasmic c-terminal domain
consisting of 76 amino acids. The extracellular domain consists of the
n-terminal, disulfide bonds, and a CSPG repeat domain.transduction, NG2 functions as a co-receptor in conjunction with
PDGFR alpha for receptor tyrosine kinase PDGF to activate focal
adhesion kinase andMAP kinase pathways [18–20]. The intracellular or
cytoplasmic domain of NG2 contains binding sites for multi-PZD
domain protein 1 (MUPP1), which facilitates the physical interaction of
NG2 with the key structural and/or signaling components in the
cytoplasm [21]. The cytoplasmic domain also contains binding sites for
synaptic protein GRIP1 and syntenin-1 that are important for NG2
mediated cellular migration [22,23]. The two phosphorylation sites on
intracellular domain, Thr 2256 and 2314 are phosphorylated by PKCα
and ERK, respectively [24]. β1 integrin-mediated signaling of cell
motility and proliferation has been shown to be balanced through
interaction with differentially phosphorylated NG2, which results in
localization of integrin protein to the cell surface [24]. Cell surface
localization is followed by β1 integrin binding to the NG2 extracellular
domain which also contains binding sites for collagens II, V, and VI,
galectin, laminin, and tenascin [25]. NG2 binding to these proteins
facilitates enhanced cellular adhesion. According to recent studies,
activity dependent sequential cleavage of NG2 by α and γ secretase
results in releasing of extracellular and intra cellular domains [17]. The
cleaved peptides will then become biologically functional molecules
regulating neuronal network by bidirectional communication between
neurons and oligodendrocyte precursors [17]. In addition, the two
conserved N-terminal domains of NG2 extracellular domain (laminin
neurexin sex-hormone binding globulin domains) were found to be
important for neuromodulation [17].
NG2 Glia Cells
Neuroglia, also known as glia, are non-neuronal cells derived from
ectoderm during embryonic development [26]. Glia are present
throughout the mammalian nervous system and maintain homeo-
stasis, form myelin, and provide support and protection for neurons
[27–29]. CNS glial cells are categorized into three types: astrocytes,
oligodendrocytes, and microglial cells [26]. More recently, a fourth
major glial cell has been identified, expressing NG2 as an integral
membrane chondroitin sulphate proteoglycan [30,31]. The NG2
glial cells are generated from neural stem cells through glial restricted
progenitors [32] and are present in large numbers throughout the
developing and mature CNS. In the developing murine brain, NG2
glial cells emerge in three different regional waves at different times
[33]. The first wave to emerge is in the ventral medial ganglionic
eminence at embryonic day (ED) 12.5 and subsequently migrate
dorsally to cerebral cortex and proliferate throughout the cortex [33].
The second wave appears around ED 16 in the lateral ganglionic
eminence and migrate to telencephalon. Cells generated during these
two waves disappear over time, but the NG2 glia formed during the
third wave of formation in the cerebral cortex at post natal day 0
survive and expand throughout the brain [33]. This proliferation and
differentiation of NG2 glial cells is regulated by Sonic-Hedgehog
signaling, helix-loop-helix, HMG domain transcription factors, and
epigenetic mechanisms regulating the expression of cell cycle genes
Cdc2 and methylation enzymes Dnmt1 [34–36]. In adult rat brain,
NG2 glia are mainly found in the corpus callosum and in the gray
matter regions [37].
The original observation that NG2 glial cells give rise to mature
oligodendrocytes in the CNS led to an initial designation of NG2-glia
cells as OPCs. However, subsequent research described NG2 glia as
bi-potential oligodendrocyte-type 2 astrocyte progenitors capable of
forming oligodendrocytes and type 2 astrocytes. These type 2
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marker A2B5 and lack astrocyte protein GFAP, and Ran2 [38,39].
Based on these observations, NG2 glia cells have more recently been
referred to as polydendrocytes [31]. Although some studies suggest
the possibility of NG2-glial generation of neurons [40,41], further
studies in support of these observations are warranted.
Microenvironment within the brain seems to contribute to the ability
of NG2 glial cells to form oligodendrocytes or astrocytes [38]. Fate
mapping of NG2 glia has been achieved using NG2creBAC:ZEG
double transgenic mice [38]. In these mice, active Cre resulted in the
constitutively expressed EGFP under the NG2 promoter. Fate mapping
showed that NG2 cells to be able to give rise to oligodendrocytes in both
gray and white matter of the brain and spinal cord [38,42,43].
Furthermore, in the gray matter of the ventral forebrain and spinal cord,
NG2 expressing glial cells give rise to protoplasmic astrocytes.
Protoplasmic astrocytes are defined by being predominantly present in
white matter, having fewer glial filaments, and exhibiting irregular
contours when compared to fibrous astrocytes [38,44].
NG2 OPCs have been reported as the glioma precursor cells in
adult gliomas [45–47]. The failure of OPCs to express asymmetric
levels of NG2 during mitotic division constitutes an important step in
glioma formation [47] (Figure 2). In healthy OPCs, only one
daughter cell inherits NG2 expression while the NG2 expression in
the second daughter cell is silenced [47]. This segregated NG2
expression is accompanied by co-expression of trophic factors
including platelet-derived growth factors (PDGF) in the pertinent
daughter cell. PDGF signaling contributes to glioma tissue
remodeling, which is known to be important for transformation of
adjacent glial cells in the local tumor microenvironment [46].
Symmetric segregation of NG2 in glioma precursors result in an
increased population of uncommitted NG2 glioma precursor cells
within the tumor, which facilitates EGF-dependent proliferation
and self-renewal.
Role of NG2 Protein in Glioma
High NG2 expression is found in human adult glioma and is
associated with aggressive disease course and poorer survival. Gliomas
are malignant tumors arising from glial cells and include astrocytoma
(arising from astrocytes), oligodendroglioma (originating from
oligodendrocytes or OPCs), and oligoastrocytoma (with mixed glialDAPI
Figure 2. Aberrant symmetric segregation of NG2 in mouse glioma
assessed for NG2 expression. Immunocytochemical assays using NG
NG2 expression in both daughter cells resulting in continuous post m
these cells. Scale bar = 5 μm.cell origin) [48]. The most common and malignant form of glioma,
Glioblastoma multiforme (GBM) is an astrocytoma, which is highly
invasive and the invasion and migration of this tumor into the CNS
involves the interaction of tumor cells with the host’s cells and
extracellular matrix molecules. Analysis of mRNA data of human
GBM samples using The Cancer Genome Atlas revealed that NG2 is
one of the highly upregulated proteoglycans [49]. NG2 expression in
GBM increases the invasive and migratory capabilities of glioma cells
by facilitating interactions with extracellular matrix proteins such as
collagen VI and laminin 2 [25,50]. NG2 interaction with collagen is
facilitated at the nonglobular domain which is modified with
glycosaminoglycan chains [50,51]. However, modification does not
play a significant role in the collagen binding of NG2. Given the
relatively low quality of collagen in the brain parenchyma, it is
plausible that NG2 may facilitate the cellular migration by binding
the vascular associated collagen VI [52]. These proteins are important
for cell adhesion and motility and thus play an important role in
progression of neoplasia. Indeed, B28 rat glioma cells expressing
mutant NG2 protein lacked collagen-binding sites and exhibited
retardation of tumor cell migration [50]. This property of NG2
protein may contribute to the highly proliferative and infiltrative
nature of diffused pontine gliomas [15]. NG2 expression in pericytes
and the basement membrane components of tumor vasculature
facilitates angiogenesis and thus tumor growth by sequestering
angiostatin, which is known to inhibit neovascularization [53]. In
glioma murine models, NG2 expression drives increased vascular
leakiness, vasogenic edema, tumor volumes, and necrosis resulting in
dysregulation of the host-derived tumor vasculature [54].
While the expression and role of NG2 in adult gliomas is well
established, little is known about role of NG2 expression in pediatric
brain tumors. A study by Chekenya and colleagues (2002) reported the
overexpression of NG2 in pediatric brain tumors that included two
medulloblastomas, which is the most common type of pediatric
malignant brain tumor occurring in the cerebellum and one pilocytic
astrocytoma, which is a benign low-grade tumor [55]. However, NG2
expression was not detected in the cell culture models of medulloblas-
toma [56,57]. Recently, differential expression ofNG2was reported in a
cohort of 57 various pediatric brain tumor samples obtained at biopsy
[57]. High NG2 expression was detected in all dysembryoplastic
neuroepithelial (DNETs) tumors, and two of the fourteenNG2 Merge
cells.Mouse glioma neurospheres were expanded in culture and
2 antibody (red) and DAPI (blue) nuclear staining showed symmetric
itotic NG2 expression which may contribute to tumorigenicity of
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including astrocytoma, pilocytic astrocytoma, ependymoma that arise
from ependymal cells lining the ventricles and spinal cord, and
supratentorial primitive neuroectodermal tumor, showed varied NG2
expression levels. We have recently shown NG2 expression to be
associated with childhood diffuse intrinsic pontine glioma (DIPG) that
occurs exclusively in children. DIPG is the most aggressive and
infiltrative form of tumor accounting for 10% to 20% of pediatric CNS
tumors. In a cohort of 50 samples obtained at postmortem, NG2
expression was detected in 78% of DIPG specimens tested [15]
(Figure 3). In accordance with the observation made by Sugiarto and
colleagues (2011), primary human and murine DIPG cells exhibited
aberrant symmetric NG2 expression, indicating their pluripotency and
tumor stem cell-like properties [15]. Moreover, NG2-expressing
primary DIPG cells showed co-expression of oligodendrocyte (Olig2)
and astrocyte (GFAP) cell markers denoting their pluripotent potential,
thought to be caused by excessive and dysregulated NG2 expression in
mitotic cells. Although these studies established NG2 expression in
various types of pediatric brain tumors, additional studies are required to
elucidate the role of NG2 expression in pediatric brain tumors.
NG2 as a Potential Target for Diagnosis
and Therapy
The ever-emerging role of NG2 in promoting angiogenesis, tumor
infiltration, and expansion warrants studies investigating its role as a
target for cancer treatment. Despite NG2 overexpression in a wide
variety of tumors such as melanomas, breast, head and neck
carcinomas, mesotheliomas, and brain tumors, recognition of
NG2’s potential therapeutic value has not been fully utilized [58].
NG2 targeting has been achieved at the expression level using RNA
interference (RNAi) and at the protein level using NG2 binding
antibodies or peptides [59–63]. Such targeting of NG2 at both
mRNA and protein levels have successfully resulted in tumor cell
apoptosis, reduced angiogenesis, and reduced tumor cell invasion
[60,61,64]. In this section, we will review few strategies used to target
NG2 expressing cancer cells.
Targeting of NG2 using RNAi can be achieved using siRNA,
shRNA, or miRNA constructs. RNAi is achieved by using small
non-coding double stranded RNA molecules resulting in degradation
of target mRNA and subsequent down-regulation of target protein
[59]. For example, siRNA mediated NG2 targeting alleviateA 
Figure 3. NG2 expression in pediatric diffuse intrinsic pontine gli
specimens obtained at autopsy from patients with DIPG. Immunohisto
tumor sample when compared to control specimen. Scale bar = 20chemoresistance and render cancerous cells to cytotoxic treatment
in vitro [59]. shRNA mediated NG2 knockdown result in normalized
vasculature, reduced tumor growth, and edema in GBM xenograft
mice [60] and reduced tumor proliferation and increased necrosis in a
murine model of melanoma [60]. Complimentary in vitro and in vivo
studies using shRNA-mediated NG2 knockdown resulted in
enhanced chemotherapy response via mitigation of β1 integrin
signaling and increased tumor cell response to cytotoxic treatment
[64]. miR129-2 is an endogenously expressed microRNA targeting
NG2 mRNA. In DIPGs, miR129-2 is down-regulated by epigenetic
(hypermethylation) regulation. We have shown that miR129-2
regulation is restored in vitro and in vivo by using either
hypomethylating drug (5-azacytidine) or lentivirus-mediated
miR129-2 transduction [15]. In both cases, NG2 protein down-
regulation resulted in reduced cellular migration [15]. However, the
limitations associated with any RNA interference based approach
such as off target effects and need for an efficient delivery system,
making it as a less favorable candidate for human use.
Immunotherapeutic approaches using the large extracellular domain
of the NG2 protein as a tumor antigen have been also explored [65].
GBMs, for example, have been effectively treated in vivo using an
intralesional adoptive cellular immunotherapy approach where
NG2-binding monoclonal antibodies (mAb9.2.27) combined with
natural killer cells were used [61,62]. Dual targeting of NG2 and GD3A
in neoplastic GBM astrocytes was also achieved using the Map-Zap
saporin immunotargeting system [66]. We have recently targeted NG2
using manganese-containing Prussian blue nanoparticles coated with
anti-NG2 antibodies and used for fluorescent and MRI imaging of
glioma cells [67]. NG2 specific monoclonal antibody also conferred
anti-tumor effect in in vitro and murine in vivo preclinical models of
triple negative breast cancer by inhibiting signaling pathways crucial for
cell survival, proliferation, and metastasis [68]. Metastatic melanoma
cells were targeted in vitro using NG2 antibodies which caused loss of
NG2 interaction with extracellular matrix components and resulted in
blockade of signal transduction pathways crucial for melanoma
metastasis [69]. A single-chain antibody scFv-FcC21 that specifically
binds to humanNG2was shown to be useful in inhibiting tumor growth
and improving survival in melanoma cell derived lung metastases mouse
model [70]. Although antibody-mediated mechanism of NG2 targeting
seems feasible, the associated disadvantages such as non-specific antibody
toxicity and antibody size (limiting diffusion across within the tumor orB
oma.Tissue sections representing healthy (A) or tumor (B) brain
chemical assays indicated high expression levels of NG2 (brown) in
μm.
Translational Oncology Vol. 9, No. 1, 2016 The Role of NG2 Proteoglycan in Glioma Yadavilli et al. 61across the blood brain barrier) have dampened enthusiasm for
translational application of antibodies. As a remedy to the relatively
large size of anti-NG2 antibody, two short peptides (TAASGVRSMH
and LTLRWVGLMS) have been designed and shown to specifically
targetNG2protein [63,71]. These deca peptides have been used for drug
delivery to tumor sites in melanoma xenografts [63]. Additionally, NG2
binding peptides provide the feasibility to explore downstream effectors
and molecular mechanisms that can be targeted to design anti-cancer
therapies.
As discussed above, NG2 expression is limited to OPCs and as
expected a developing child’s brain contains a larger number of NG2
expressing OP cells. One critical question in targeting NG2 in pediatric
gliomas is the potential of such approach in destroying healthy OPCs
that are important for the developing brain of a child.However, a limited
number of studies indicate the differential expression ofNG2 isoforms in
adult GBM when compared to fetal and healthy adult brain [72].
Specifically, Girolamo and colleagues documented 48 immunologically
distinct NG2 isoforms, 14 of which were present in the fetal and
neoplastic cerebral sections and absent in the adult brains [72]. Further
characterization of these isoforms is warranted using more sensitive
platforms such as mass spectroscopy to ensure the specific expression of
these isoforms in various tissue and tumor types.
Conclusion
Despite the fact that NG2 is being widely used as a potential targeting
molecule in in vivo and in vitro pre-clinical studies, substantial evidence
has not yet been established for NG2’s utility in clinical studies and in
treating human disease. Due to its role in maintaining a pluripotent pool
of tumor cells, and its role in tumor migration and infiltration, NG2
provides multiple avenues for developing therapeutics. Moreover, the
large extracellular domain of NG2 provides an excellent antigen
repertoire for immunotherapeutic interventions. As such, further
research is warranted to define the role and expression regulation of
NG2 in CNS cancers.
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